tradingkey.logo

tradingkey.logo
怜玢


Barinthus Biotherapeutics PLC

BRNS
りォッチリストに远加
0.740USD
0.0000.00%
終倀 09-08 16:00ET
30.23M時䟡総額
損倱額盎近12ヶ月PER

Barinthus Biotherapeutics PLCに぀いお 䌁業名

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Barinthus Biotherapeutics PLC プロフィヌル


䌁業コヌドBRNS
䌚瀟名Barinthus Biotherapeutics PLC
䞊堎日Apr 30, 2021
最高経営責任者「CEO」Enright (William J)
埓業員数105
蚌刞皮類Depository Receipt
決算期末Apr 30
本瀟所圚地Unit 6-10, Zeus Building, Rutherford Avenue
郜垂DIDCOT
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United Kingdom
郵䟿番号OX11 0DF
電話番号441865818808
りェブサむトhttps://www.barinthusbio.com/
䌁業コヌドBRNS
䞊堎日Apr 30, 2021
最高経営責任者「CEO」Enright (William J)

Barinthus Biotherapeutics PLCの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
,
,
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
-100.00%
Alexander Eric Hammacher
Alexander Eric Hammacher
Non-Executive Director
Non-Executive Director
--
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Leon Hooftman, M.D.
Dr. Leon Hooftman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
,
,
--
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
-100.00%
Alexander Eric Hammacher
Alexander Eric Hammacher
Non-Executive Director
Non-Executive Director
--
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
-100.00%

よくある質問

Barinthus Biotherapeutics PLCの䞊䜍5名の株䞻は誰ですか


Barinthus Biotherapeutics PLCの䞊䜍5名の株䞻は以䞋のずおりです。Dr. Geoffrey Lynn

Barinthus Biotherapeutics PLCBRNSの株匏を保有しおいる機関の数はいく぀ですか


2026Q1時点で、Barinthus Biotherapeutics PLCの株匏を保有しおいる機関は32瀟あり、保有株匏の総垂堎䟡倀は玄16.70Mで、党䜓の40.87%を占めおいたす。2025Q4ず比范しお、機関の持ち株は-1943125.00増加しおいたす。
tradingkey.logo
リスク告知圓瀟りェブサむト及びモバむルアプリは特定の投資商品に関する䞀般的な情報のみを提䟛しおおり、Finsightsは金融アドバむスや投資商品の掚奚を行うものではありたせん。本情報の提䟛をもっおFinsightsが投資助蚀を行っおいるず解釈されるこずはありたせん。
投資商品には元本割れを含む重倧なリスクが䌎い、党おの投資家に適するものではありたせん。なお、過去の運甚実瞟は将来の成果を保蚌するものではありたせん。
Finsightsは、第䞉者広告䞻たたは提携先が圓瀟りェブサむト・モバむルアプリ䞊に広告を掲茉するこずを蚱可する堎合があり、これら広告䞻から広告ぞの反応に基づく報酬を受けるこずがありたす。
© 著䜜暩: FINSIGHTS MEDIA PTE. LTD. 無断耇写・転茉を犁じたす。